Thermo Fisher Closes $8.9 Billion Clario Deal To Strengthen Clinical Trial Data And Biopharma Services Portfolio

Thermo Fisher Scientific has finalised its acquisition of Clario Holdings in a deal valued at $8.875 billion in cash, with additional earnout and performance-based payments possible. Following the close, Clario will operate within Thermo Fisher’s Laboratory Products and Biopharma Services segment, strengthening the company’s clinical research capabilities.

Clario specialises in endpoint data solutions that support clinical trials by digitally integrating data from patients, research sites, and medical devices. Its platforms enable pharmaceutical and biotech sponsors to efficiently gather, manage, and analyse clinical evidence across all phases of drug development, helping accelerate decision-making and innovation. Over the past decade, Clario’s technologies have contributed to around 70% of novel drug approvals by the U.S. Food and Drug Administration and the European Medicines Agency.

“We are excited to welcome Clario’s talented colleagues to Thermo Fisher,” said Marc N. Casper, chairman and chief executive officer of Thermo Fisher Scientific. “Clario is an outstanding strategic fit for our company, enhancing our ability to enable faster, more informed drug development through differentiated technology and data intelligence solutions.”

Thermo Fisher highlighted the strong financial profile of the acquisition, projecting high single-digit revenue growth and margin expansion benefits. The deal is expected to deliver a double-digit internal rate of return and improve adjusted operating margins. In its first year post-close, the acquisition is projected to add $0.45 to adjusted earnings per share, with further financial details to be outlined in the company’s upcoming earnings update.

The company anticipates generating approximately $175 million in adjusted operating income synergies within five years, driven primarily by revenue opportunities from combined capabilities. Clario was purchased from an investor consortium led by Astorg and Nordic Capital, alongside Novo Holdings and Cinven. Beyond the upfront payment, Thermo Fisher will pay $125 million in early 2027 and up to $400 million in additional earnouts tied to Clario’s performance milestones through 2027.